Back
Blueprint Medicines Stock Price Chart
Sponsored
BPMC
Sponsored
2025 Gold Forecast: A Perfect Storm for Demand
Discover our Gold Price Outlook for 2025--FREE--here
Sell
27
BPMC
Blueprint Medicines
Last Price:
$91.65
Seasonality Move:
2.18%
7 Day Trial
ALL ACCESS PASS
$
7
FREE REPORT: 2025 Gold Price Outlook
Get Your Copy of "2025 Gold Forecast: A Perfect Storm for Demand" Here.-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BPMC is experiencing buying pressure, which is a positive indicator for future bullish movement.
Blueprint Medicines Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 91.9 | Sell |
20-day SMA: | 93.93 | Sell |
50-day SMA: | 92.53 | Sell |
200-day SMA: | 96.72 | Sell |
8-day EMA: | 91.64 | Sell |
20-day EMA: | 92.89 | Sell |
50-day EMA: | 93.08 | Sell |
200-day EMA: | 91.72 | Sell |
Blueprint Medicines Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.82 | Sell |
Relative Strength Index (14 RSI): | 46.21 | Sell |
Chaikin Money Flow: | 190165 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (91.78 - 96.44) | Sell |
Bollinger Bands (100): | (87.55 - 95.79) | Sell |
Blueprint Medicines Technical Analysis
Dec 12 | Dec 13 | Dec 16 | Dec 17 | Dec 18 | Dec 19 | Dec 20 | Dec 23 | Dec 24 | Dec 26 | |
---|---|---|---|---|---|---|---|---|---|---|
Dec | ||||||||||
12 | 13 | 16 | 17 | 18 | 19 | 20 | 23 | 24 | 26 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 91.62 while BPMC 8-day simple moving average is 91.90, which is a Sell signal.
-
The stock price of BPMC is 91.62 while Blueprint Medicines 20-day SMA is 93.93, which makes it a Sell.
-
Blueprint Medicines 50-day simple moving average is 92.53 while BPMC share price is 91.62, making it a Sell technically.
-
BPMC stock price is 91.62 and Blueprint Medicines 200-day simple moving average is 96.72, creating a Sell signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
27
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $91.62. The Score for BPMC is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
5.8B
Price in USD:
91.62
Share Volume:
267.9K
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
72.24
Sell
27
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 91.62 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 91.62 while BPMC 8-day exponential moving average is 91.64, which is a Sell signal.
-
The stock price of BPMC is 91.62 while Blueprint Medicines 20-day EMA is 92.89, which makes it a Sell.
-
Blueprint Medicines 50-day exponential moving average is 93.08 while BPMC share price is 91.62, making it a Sell technically.
-
BPMC stock price is 91.62 and Blueprint Medicines 200-day simple moving average is 91.72, creating a Sell signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.73 per share, a decrease next quarter of $0.00 per share, an increase this year of $7.18 per share, and an increase next year of $0.57 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is -0.82, suggesting Blueprint Medicines is a Sell
-
Blueprint Medicines Relative Strength Index (RSI) is 46.21, which suggest Blueprint Medicines is oversold
-
The Bollinger Bands (25) for Blueprint Medicines is (91.78 - 96.44), which suggest Blueprint Medicines is a Sell
-
The Bollinger Bands (100) for Blueprint Medicines is (87.55 - 95.79), which suggest Blueprint Medicines is a Sell
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.